Michaela Dinan, PhD
Associate Professor TenureDownloadHi-Res Photo
Cards
Additional Titles
Co-Leader, Cancer Prevention and Control, Yale Cancer Center
Contact Info
Chronic Disease Epidemiology
PO Box 208034, 60 College St
New Haven, CT 06520
United States
About
Titles
Associate Professor Tenure
Co-Leader, Cancer Prevention and Control, Yale Cancer Center
Biography
Dr. Michaela Dinan is an Associate Professor of Epidemiology in the Yale School of Public Health, and Co-Leader of the Cancer Prevention and Control Research Program at the Yale Comprehensive Cancer Center, Yale School of Medicine. She is also a member of the Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center. Dr. Dinan has extensive research expertise in leveraging existing real-world data sources as well as novel data linkages to examine oncology outcomes.
Dr. Dinan is a health services researcher by training and she specializes in using econometric and epidemiologic methodologies to analyze complex datasets. Specifically, Dr. Dinan's research involves issues related to advances in cancer care technologies, such as emerging treatments and diagnostics, and how these advances in technologies impact different cancer outcomes and experiences such as access, quality of care, cost of care, and health disparities.
Dr. Dinan has led studies funded by the National Institutes of Health, the American Cancer Society, and the Agency for Healthcare Research and Quality. She is currently leading an NCI-funded R01 study examining multi-level factors that contribute to disparities in access and adherence to oral anticancer agents for patients with kidney cancer. Dr. Dinan is also leading a study funded by the ACS to develop and validate risk prediction algorithms to inform efficient and high-quality care for long-term cancer survivors.
Appointments
Chronic Disease Epidemiology
Associate Professor TenurePrimary
Other Departments & Organizations
- Cancer Prevention and Control
- Chronic Disease Epidemiology
- Chronic Disease Epidemiology (CDE)
- COPPER Center
- Public Health Data Science and Data Equity
- Yale Cancer Center
- Yale School of Public Health
- Yale School of Public Health - NEW
Education & Training
- PhD
- University of North Carolina, Health Policy and Management (2011)
Research
Overview
Dr. Dinan has extensive research expertise in leveraging existing real-world data sources as well as novel data linkages to examine oncology outcomes. She is a health services researcher with training in econometric and epidemiologic methodologies to analyze complex datasets. Specifically, Dr. Dinan's research involves issues related to access and quality of care, health disparities, and cost of care for cancer patients.
Medical Research Interests
Breast Neoplasms; Cancer Survivors; Carcinoma, Renal Cell; Chronic Disease; Colonic Neoplasms; Costs and Cost Analysis; Epidemiology; Risk Assessment; Urologic Neoplasms
Public Health Interests
Health Equity, Disparities, Social Determinants and Justice; Health Policy; Chronic Diseases; Aging; Cancer; Women's Health; Pharmacoepidemiology
ORCID
0000-0003-4849-4743
Research at a Glance
Yale Co-Authors
Frequent collaborators of Michaela Dinan's published research.
Publications Timeline
A big-picture view of Michaela Dinan's research output by year.
Research Interests
Research topics Michaela Dinan is interested in exploring.
Cary Gross, MD
Michael S. Leapman, MD, MHS
Michael Hurwitz, MD, PhD
Timothy Robinson, MD, PhD
Xiaomei Ma, PhD
Henry S. Park, MD, MPH
152Publications
4,063Citations
Breast Neoplasms
Carcinoma, Renal Cell
Risk Assessment
Cancer Survivors
Costs and Cost Analysis
Chronic Disease
Publications
2024
Association between mammographic screening history and stage at diagnosis among women with screen-detected breast cancer.
Huang S, Westvold S, Soulos P, Winer E, Robinson T, Dinan M. Association between mammographic screening history and stage at diagnosis among women with screen-detected breast cancer. Journal Of Clinical Oncology 2024, 20: 145-145. DOI: 10.1200/op.2024.20.10_suppl.145.Peer-Reviewed Original ResearchConceptsScreen-detected breast cancerBreast cancer mortalityScreening historyScreening mammographyScreening mammogramsCancer mortalityFee-for-service Medicare Parts ABreast cancerBreast cancer-specific mortalityScreening prior to diagnosisNon-Hispanic black raceNegative screening mammogramCohort study of womenFactors associated with increased oddsAssociated with lower riskRetrospective cohort study of womenRoutine screening mammographyMedicare Part AHigh school educationStudy of womenCancer-specific mortalityMultivariate logistic regressionSEER-Medicare databaseClaims-based algorithmSporadic screeningStrength of evidence underlying the CMS-FDA parallel review of comprehensive genomic profiling tests in the cancer setting
Stackland S, Schnabel D, Dinan M, Presley C, Gross C. Strength of evidence underlying the CMS-FDA parallel review of comprehensive genomic profiling tests in the cancer setting. Journal Of The National Cancer Institute 2024, djae196. PMID: 39288939, DOI: 10.1093/jnci/djae196.Peer-Reviewed Original ResearchCitationsAltmetricConceptsComprehensive genomic profilingComprehensive genomic profiling testCenter for Medical Technology PolicyClinical careClinical outcomesDiagnostic testsAssessed clinical outcomesOutcomes of patientsStrength of evidenceCourse of clinical careEfficacy of diagnostic testsNovel diagnostic testsPeer-reviewed literatureGenomic profiling testsFoundationOne CDxGenomic testingSolid tumorsStudy designGenomic alterationsGenomic profilingF1CDxCancer settingClinical utilityCancer typesCompare groupsCost trends of metastatic renal cell carcinoma therapy: the impact of oral anticancer agents and immunotherapy
Forman R, Long J, Westvold S, Agnish K, McManus H, Leapman M, Hurwitz M, Spees L, Wheeler S, Gross C, Dinan M. Cost trends of metastatic renal cell carcinoma therapy: the impact of oral anticancer agents and immunotherapy. JNCI Cancer Spectrum 2024, 8: pkae067. PMID: 39133171, PMCID: PMC11376369, DOI: 10.1093/jncics/pkae067.Peer-Reviewed Original ResearchAltmetricConceptsMetastatic renal cell carcinomaOral anticancer agentsOAA useAssociated with decreased adherenceRenal cell carcinomaAnticancer agentsDays of treatmentCombination therapyCell carcinomaStudy patientsInitial treatmentReal-world costsCombination groupImmunotherapyPatientsOOP costsTherapyTreatment typePercent daysPerspective of payersTreatmentClaims dataMedicare patientsAnalyzed differencesFee-for-service MedicareChanges in Facility Share of Medicaid-insured Patients With Urologic Cancers Following Implementation of the Patient Protection and Affordable Care Act
Demkowicz P, Buck M, Nie J, Marks V, Wheeler S, Dinan M, Gross C, Leapman M. Changes in Facility Share of Medicaid-insured Patients With Urologic Cancers Following Implementation of the Patient Protection and Affordable Care Act. Urology 2024, 192: 19-27. PMID: 38901803, DOI: 10.1016/j.urology.2024.06.003.Peer-Reviewed Original ResearchCitationsConceptsFacility-level changesAffordable Care ActNon-expansion statesUrological cancer patientsProportion of patientsExpansion statesBaseline proportion of patientsUrologic cancer careHigh-income zip codesCancer patientsFactors associated with changesPre-post designCancer care centerPost-ACA periodMedicaid expansion statesMultivariate logistic regressionMedicaid-insured patientsCancer careUrological cancersZip codesCare ActMedicaid patientsMedicaidLogistic regressionCare centerCharacterization of time toxicity in older patients with metastatic breast cancer
Atre S, Soulos P, Kuderer N, Gross C, Baum L, Dinan M, Lustberg M. Characterization of time toxicity in older patients with metastatic breast cancer. Breast Cancer Research And Treatment 2024, 207: 541-550. PMID: 38816556, DOI: 10.1007/s10549-024-07379-7.Peer-Reviewed Original ResearchCitationsConceptsMetastatic breast cancerBone-modifying agentsComorbid medical conditionsOlder patientsBreast cancerRetrospective cohort studySEER-Medicare databaseTreatment typeCancer treatment modalityTreatment modalitiesSEER-MedicareCohort studyUnadjusted analysisPatientsAge-related impactCancer treatmentComorbiditiesDay patientsCancerRadiotherapyOlder ageMedical conditionsToxicityTreatmentSociodemographic factorsOpioid prescribing trends and pain scores among adult patients with cancer in a large health system.
Baum L, Soulos P, KC M, Jeffery M, Ruddy K, Lerro C, Lee H, Graham D, Liberatore M, Rivera D, Leapman M, Jairam V, Dinan M, Gross C, Park H. Opioid prescribing trends and pain scores among adult patients with cancer in a large health system. Journal Of Clinical Oncology 2024, 42: 11059-11059. DOI: 10.1200/jco.2024.42.16_suppl.11059.Peer-Reviewed Original ResearchConceptsDocumented painHealth systemOpioid prescribingOpioid prescriptionsOpioid prescribing trendsYale New Haven Health SystemPrescribing trendsMetastatic cancerDocumented pain scoresUS health systemOpioid usePain scoresAdult patientsCalculated predicted probabilitiesFlowsheet dataRetrospective cohort studyRelated harmSolid tumor malignanciesCohort studyCancer painPrescribingContext of cancer treatmentStudy criteriaPainSurgery cohortPersonalized risk assessment of new onset depression in long-term cancer survivors.
Taylor M, Westvold S, Long J, Hyslop T, Wang S, Cecchini M, Leapman M, Leeds I, Lustberg M, Spees L, Wheeler S, Gross C, Oeffinger K, Dinan M. Personalized risk assessment of new onset depression in long-term cancer survivors. Journal Of Clinical Oncology 2024, 42: e13798-e13798. DOI: 10.1200/jco.2024.42.16_suppl.e13798.Peer-Reviewed Original ResearchConceptsHistory of depressionIncidence of depressionCumulative incidence of depressionRisk of developing depressionLong-term survivorsPredictors of depressionCancer survivorsDisease specific factorsCumulative incidenceNon-HispanicHigher risk of developing depressionRectal cancerLong-term cancer survivorsBreast cancer survivorsCensus tract povertyColon cancerEpisodes of bipolar I disorderPrevalence of depressionMean survival time modelsDiagnosis of depressionReceipt of treatmentAssociated with prior historyHormone receptor statusPatients aged <Adjuvant endocrine therapyACO leakage among gynecologic cancer patients: Incidence, predictors, and impact on annual Medicare expenditure
Osazuwa-Peters O, Greiner M, Kaufman B, Zambrano Guevara L, Dinan M, Havrilesky L, Moss H. ACO leakage among gynecologic cancer patients: Incidence, predictors, and impact on annual Medicare expenditure. Gynecologic Oncology 2024, 187: 184-191. PMID: 38788516, DOI: 10.1016/j.ygyno.2024.05.020.Peer-Reviewed Original ResearchConceptsAccountable care organizationsGynecologic cancer patientsACO sizeYear of cancer diagnosisReceipt of healthcareLog-binomial regression modelsCancer patientsNon-ACO providersPatients seeking careAdjusted risk ratiosHealth care costsAnnual Medicare expendituresMedian household incomeAssociated with useCare organizationsOutpatient careMedicare expendituresCare costsHealthcare costsMedicare spendingCancer diagnosisOutpatient settingHousehold incomeRisk ratioMultivariable adjusted risk ratiosArea Vulnerability and Disparities in Therapy for Patients With Metastatic Renal Cell Carcinoma
Rahman S, Long J, Westvold S, Leapman M, Spees L, Hurwitz M, McManus H, Gross C, Wheeler S, Dinan M. Area Vulnerability and Disparities in Therapy for Patients With Metastatic Renal Cell Carcinoma. JAMA Network Open 2024, 7: e248747. PMID: 38687479, PMCID: PMC11061765, DOI: 10.1001/jamanetworkopen.2024.8747.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsMetastatic renal cell carcinomaArea-level measuresRenal cell carcinomaPatient-level factorsSystemic therapyEthnic disparitiesRelative risk ratiosSocially vulnerable areasCell carcinomaMeasures of social vulnerabilityMedicare beneficiariesCohort studyFee-for-service Medicare Parts AOdds ratioReceipt of systemic therapyLogistic regressionArea-level characteristicsAssociated with lack of treatmentNon-Hispanic blacksRetrospective cohort studyIndividual-level demographicsNon-Hispanic whitesAssociated with disparitiesUS Medicare beneficiariesMeasures of disadvantage
2023
Total and treatment-related costs of care associated with in patients with metastatic renal cell carcinoma receiving targeted or immune therapy.
Rahman S, Long J, Westvold S, Wheeler S, Spees L, Leapman M, Hurwitz M, McManus H, Gross C, Dinan M. Total and treatment-related costs of care associated with in patients with metastatic renal cell carcinoma receiving targeted or immune therapy. JCO Oncology Practice 2023, 19: 28-28. DOI: 10.1200/op.2023.19.11_suppl.28.Peer-Reviewed Original ResearchCitationsAltmetricConceptsMetastatic renal cell carcinomaOral anticancer agentsInitial treatmentRetrospective cohort studyUse of immunotherapyYear of diagnosisRenal cell carcinomaDirect treatment costsMean Medicare paymentsMedicare paymentsMedicare Part DInitial therapyCohort studyMetastatic diagnosisCell carcinomaCombination therapyImmunotherapyMedicare beneficiariesPatientsAge 65Disease controlOlder ageStudy periodTherapyDiagnosis
News
News
- December 23, 2024
Yale Cancer Answers with Dr. Michaela Dinan: Emerging Trends in Cancer Care Outcomes
- December 17, 2024
YCC Publications 2024
- September 20, 2024
Are Comprehensive Genetic Profiles Helping Patients with Cancer?
- May 16, 2024
2024 Top Faculty Awards Announced
Get In Touch
Contacts
Academic Office Number
Mailing Address
Chronic Disease Epidemiology
PO Box 208034, 60 College St
New Haven, CT 06520
United States
Locations
Ste 444
Academic Office
60 College Street
New Haven, CT 06510